SGLT2 Inhibitors (Gliflozins)
PharmaceuticalLast reviewed on June 1, 2026 by SupStaq
Not medical advice. This content is general, evidence-based information and is not a substitute for professional medical advice, diagnosis, or treatment.
The medical score is considerably higher, as dozens of large RCTs and guideline recommendations clearly establish cardiorenal efficacy [s4, s5, s6]. Community users without diabetes rate the benefit for their population lower, given the absence of clinical evidence in healthy individuals and the perception of side effects such as genital infections as burdensome [c1, c3].
Unlock full information
Dosages, side effects, studies and more, free after registration.
Register for freeRating Scales
TL;DR
SGLT2 inhibitors are among the best-evidenced drugs in modern internal medicine: empagliflozin and dapagliflozin consistently reduce heart failure hospitalizations, CKD progression, and cardiovascular mortality in large RCTs — regardless of diabetes status. The off-label longevity hype for healthy non-diabetics, however, has no clinical trial support. Risks like euglycemic ketoacidosis (especially on ketogenic diets) and Fournier's gangrene are rare but serious enough to warrant respect. Prescription-only, no statutory health insurance coverage outside approved indications — off-label use comes entirely at the patient's own cost and risk.
Description
Prescription antidiabetics that inhibit SGLT2 in the renal tubule, demonstrating blood glucose-lowering as well as cardio- and nephroprotective effects [s1, s2].
SGLT2 inhibitors (gliflozins) are a class of orally administered medications that selectively inhibit the sodium-glucose cotransporter 2 (SGLT2) in the proximal renal tubule. This transporter is responsible for the reabsorption of approximately 90% of glomerularly filtered glucose. By inhibiting it, glucose is increasingly excreted in the urine (glucosuria), resulting in insulin-independent blood glucose reduction [s1, s3]. Clinically approved agents in the EU and DACH region include: empagliflozin (Jardiance), dapagliflozin (Forxiga/Edistride), canagliflozin (Invokana, temporarily not marketed in Germany), and sotagliflozin (dual SGLT1/2 inhibitor, EU approval for heart failure) [s11, s12]. Ertugliflozin and bexagliflozin are approved primarily in North America [s7]. This drug class has evolved from pure antidiabetics into cardiorenal-metabolic protective agents. Pivotal trials such as EMPA-REG OUTCOME (empagliflozin in T2DM with high cardiovascular risk), DAPA-HF (dapagliflozin in heart failure), EMPEROR-Reduced, CREDENCE, and DAPA-CKD demonstrate substantial reductions in cardiovascular events, heart failure hospitalizations, and renal endpoints — independent of diabetes status [s4, s5, s6, s8] [s9]. In biohacker and longevity circles, gliflozins are discussed as potential caloric restriction mimetics. This antidiabetic class activates metabolic pathways similar to caloric restriction (AMPK, mTOR inhibition, ketogenesis); however, clinical evidence for life extension in healthy non-diabetics is currently entirely lacking [s13, s14].
Legal Status (DE)
All approved SGLT2 inhibitors (empagliflozin/Jardiance, dapagliflozin/Forxiga, canagliflozin/Invokana) are prescription-only medications (Rx) in Germany, Austria, and Switzerland. Approval was granted by the EMA for the EU and by Swissmedic in Switzerland. The BfArM and EMA have issued multiple risk communications (Dear Healthcare Professional letters) regarding ketoacidosis, Fournier's gangrene, and amputation risk [s11, s12]. Off-label use outside approved indications is legal in Germany but requires a physician's prescription and falls outside the scope of statutory health insurance (GKV) coverage.
Mechanism of Action
SGLT2 inhibitors selectively inhibit the sodium-glucose cotransporter 2 in segments S1 and S2 of the proximal renal tubule, preventing glucose reabsorption from the glomerular filtrate and resulting in a daily glucosuria of approximately 70–90 g [s1, s3]. Direct renal effects: - Glucosuria → osmotic diuresis → reduction in blood pressure (~3–5 mmHg systolic) and body weight (~1.5–2.5 kg) [s6, s10] - Tubuloglomerular feedback: restoration of sodium delivery to the macula densa → afferent arteriolar constriction → reduction of intraglomerular pressure → nephroprotection [s3] - Reduction of uric acid via competitive inhibition of the URAT1 transporter [s1] Cardiovascular and metabolic effects: - Hemodynamic cardiac unloading through preload and afterload reduction [s4] - Mildly ketogenic metabolic state: elevated beta-hydroxybutyrate levels as a more efficient myocardial substrate ("superfuel hypothesis") [s13] - Reduction of inflammation and oxidative stress (preclinical data) [s13] - Activation of AMPK, inhibition of mTORC1, modulation of sirtuins — signaling pathways associated with caloric restriction [s13, s14] - Reduction of cellular senescence in preclinical models [s14] The precise molecular mechanism of cardiovascular protection has not yet been fully elucidated and remains the subject of ongoing research [s3].
Dosing
Typ-2-Diabetes mellitus (Blutzuckerkontrolle)
- Dose
- Empagliflozin 10 mg (increase to 25 mg possible); dapagliflozin 10 mg; canagliflozin 100–300 mg
- Frequency
- 1× täglich
- Route
- oral
- Duration
- fortlaufend
- Timing
- Morning, with or without food
- With food
- optional
Herzinsuffizienz (HFrEF und HFpEF, mit oder ohne Diabetes)
- Dose
- Dapagliflozin 10 mg or empagliflozin 10 mg
- Frequency
- 1× täglich
- Route
- oral
- Duration
- fortlaufend
- Timing
- Morning, with or without food
- With food
- optional
Chronische Nierenerkrankung (CKD)
- Dose
- Dapagliflozin 10 mg; empagliflozin 10 mg (at eGFR ≥20 ml/min/1.73 m²)
- Frequency
- 1× täglich
- Route
- oral
- Duration
- fortlaufend
- Timing
- Morning, with or without food
- With food
- optional
Maximum doses: empagliflozin 25 mg/day; dapagliflozin 10 mg/day; canagliflozin 300 mg/day. At eGFR < 20 ml/min/1.73 m², use should be reviewed per the prescribing information; at eGFR < 15, use is generally contraindicated [s1, s7].
Off-label use in healthy non-diabetics (e.g., for longevity, weight loss) is not supported by clinical trials and should only be undertaken under medical supervision. The antihyperglycemic effect diminishes with declining eGFR [s1].
Side Effects
| Side Effect | Frequency | Severity |
|---|---|---|
| Genitale Pilzinfektionen (Vulvovaginitis, Balanitis) Increased glucosuria promotes fungal growth in the urogenital area. Incidence of 58 events/1000 person-years in a retrospective study [s16]. | häufig | leicht |
| Harnwegsinfektionen (UTI) Glucose-rich environment promotes bacterial colonization of the urinary tract. Highest incidence of urogenital adverse events (62 events/1000 person-years) [s16]. | häufig | leicht |
| Euglykämische diabetische Ketoazidose (euDKA) Can occur despite near-normal blood glucose levels, making it difficult to detect. BfArM and EMA have initiated a risk assessment procedure following >100 reported serious cases [s11]. Risk increased during fasting periods, perioperative phases, and low-carbohydrate diets. | selten | schwer |
| Fournier-Gangrän (nekrotisierende Fasziitis des Perineums) Very rare, life-threatening infection. BfArM Dear Healthcare Professional Letter for the SGLT2 inhibitor class [s12]. | selten | schwer |
| Hypoglykämie (bei Kombination mit Insulin oder Sulfonylharnstoffen) SGLT2 inhibitors alone do not cause hypoglycemia; however, the risk is increased in combination with insulin or sulfonylureas [s18, s19]. | gelegentlich | moderat |
| Hypotonie und Dehydratation (insbesondere bei älteren Patienten) Osmotic diuresis due to glucosuria and natriuresis can lead to dizziness and circulatory problems when combined with diuretic use or inadequate fluid intake [s20]. | gelegentlich | moderat |
| Akuter Anstieg des Serumkreatinins (transient) Hemodynamic effect on glomerular filtration; the increase is usually transient and not indicative of renal damage [s16]. | gelegentlich | leicht |
| Amputationen der unteren Extremitäten (vorwiegend Canagliflozin) Primarily described for canagliflozin. EMA and BfArM recommended corresponding warning labels in the product information [s12]. | selten | schwer |
| Knochenbrüche (vorwiegend Canagliflozin) Possible association with reduced bone density, observed primarily with canagliflozin in studies [s17]. | selten | moderat |
Contraindications
Markedly increased risk of ketoacidosis. Dapagliflozin was withdrawn from the EU market for T1DM in 10/2021 (Dear Healthcare Professional letter) [s12].
Adequate antihyperglycemic efficacy not achievable and increased risk of adverse effects per summary of product characteristics [s1, s7].
SGLT2 inhibitors significantly increase the rate of urogenital infections; patients with a predisposition to infections should be carefully evaluated [s16, s17].
Increased euDKA risk due to fasting and stress metabolism; SGLT2 inhibitors should be discontinued 3–4 days preoperatively [s1, s11].
Not recommended; insufficient safety data; animal studies indicate renal developmental toxicity [s1].
Anaphylactic reactions and angioedema have been reported; contraindication per summary of product characteristics [s20].
Interactions
Synergistic
Additive HbA1c reduction (~0.8% additional), greater weight loss (~1.5 kg), and blood pressure reduction (~2.9 mmHg systolic) in RCTs [s10].
Complementary mechanisms of action (hepatic gluconeogenesis inhibition + increased renal glucose excretion); established combination therapy per ADA guidelines [s15].
Additive nephroprotection via complementary mechanisms (RAAS inhibition + intraglomerular pressure reduction via tubuloglomerular feedback) [s9].
Berberine and SGLT2 inhibitors may complement each other in their glucose-lowering effects, as they act via distinct mechanisms. Studies show that berberine improves insulin sensitivity and supports pancreatic function, while SGLT2 inhibitors increase renal glucose excretion. The combination may have additive effects on HbA1c and lipid levels.
Alpha-lipoic acid improves insulin sensitivity via antioxidant mechanisms and may complement the glucose-lowering effect of SGLT2 inhibitors. Both substances act via different pathways and could be additive in reducing oxidative stress and improving glucose metabolism. Clinical data on the combination are limited to date.
Inositol improves insulin sensitivity via the phosphatidylinositol signaling pathway and may complement the effect of SGLT2 inhibitors on glucose metabolism. Available sources report no known adverse interactions. The combination may act additively in metabolic syndrome and PCOS.
Caution
Increased risk of hypoglycemia; dose reduction of insulin secretagogues or insulin required [s18, s19].
Additive diuretic effect may lead to dehydration, hypotension, and electrolyte disturbances; particularly in elderly patients [s20].
Enzyme induction may reduce plasma concentrations of canagliflozin and dapagliflozin and diminish efficacy [s21].
Additive blood pressure reduction; closely monitor blood pressure in patients on existing antihypertensive therapy [s20].
Combination of berberine with SGLT2 inhibitors carries an increased risk of hypoglycemia, particularly when additional glucose-lowering agents are taken concurrently. Berberine alone already has a measurable glucose-lowering potential. Close blood glucose monitoring is recommended.
SGLT2 inhibitors can reduce the risk of hyperkalemia, which may affect electrolyte balance when combined with potassium supplementation. Potassium intake should be monitored particularly when co-administered with ACE inhibitors or ARBs.
Studies
Tier A: High Evidence
Community Evidence
Top reported benefits
- Moderate weight loss even without diabetes (1–3 kg reported)
- Mild blood pressure reduction
- Improved fasting blood glucose in pre-diabetic users
- Subjectively increased energy and reduced sense of inflammation
- Positive effects on heart failure symptoms (patient-reported)
Top reported issues
- Genital yeast infections frequently reported, perceived as bothersome
- Frequent urge to urinate, especially during the initial adaptation phase
- Concerns regarding ketoacidosis risk on a ketogenic diet
- Skepticism toward commercial off-label longevity programs
- Difficult procurement without a medical prescription
Several Reddit users in r/longevity note that no clinical evidence for life extension in healthy non-diabetics exists [c3]. One user in the r/longevity forum criticized a lack of transparency from a commercial longevity provider regarding the specific agent prescribed [c3]. German-language forums are dominated by questions about off-label prescribability and insurance coverage [c4].
Scientific Sources
- Sodium-Glucose Transport 2 (SGLT2) Inhibitors
Scheen AJ, et al. (2023). StatPearls, NCBI BookshelfBLink - Effect of Sodium-Glucose Cotransport-2 Inhibitors on Blood Pressure in People With Type 2 Diabetes Mellitus: A Systematic Review and Meta-Analysis of 43 Randomized Control Trials With 22 528 Patients
Ramirez-Garcia A, Saurina-Sole A, et al. (2016). Journal of the American Heart AssociationADOI - SGLT2-Inhibitoren: Risikobewertung diabetischer Ketoazidosen
BfArM (Bundesinstitut für Arzneimittel und Medizinprodukte) (2016). BfArM RisikoinformationALink - SGLT2-Inhibitoren: Risiko für Amputationen, Fournier-Gangrän, Dapagliflozin T1DM-Rücknahme
BfArM / EMA CHMP (2021). BfArM Risikoinformation / EMA CHMPALink - SGLT2 Inhibitors as Calorie Restriction Mimetics: Insights on Longevity Pathways and Age-Related Diseases
Cowie MR, Fisher M (2021). Endocrinology (Oxford Academic)BPMID:33857309DOI - Repurposing SGLT-2 Inhibitors to Target Aging: Available Evidence and Molecular Mechanisms
Mone P, Lombardi A, Gambardella J, et al. (2022). PubMed / IJMS or similarBPMID:36293181 - Standards of Medical Care in Diabetes — 2026 / ADA Guidelines
American Diabetes Association (2026). Diabetes CareALink - Adverse Events of Sodium-Glucose Cotransporter-2 Inhibitors in Chronic Kidney Disease: A Retrospective Chart Review
Gupta R, Walunj SS, Tokayer A, et al. (2021). PubMedBPMID:33970086 - Clinical Recommendations for Managing Genitourinary Adverse Effects in Patients Treated with SGLT-2 Inhibitors: A Multidisciplinary Expert Consensus
Moris L, Moris D, et al. (2024). Journal of Clinical Medicine (MDPI)BDOI - Sodium-Glucose Transport 2 (SGLT2) Inhibitors – Drug Interactions: StatPearls
Scheen AJ, et al. (2023). StatPearls, NCBI BookshelfBLink - Pharmacokinetic Landscape and Interaction Potential of SGLT2 Inhibitors: Bridging In Vitro Findings and Clinical Implications
Stiburkova B, Silhavy J, et al. (2025). Pharmaceutics (MDPI)BDOI - SGLT-2-Inhibitoren (Gliflozine) – Wirkstoffgruppenübersicht
Gelbe Liste Redaktion (2024). Gelbe ListeBLink - Managing the side effects of sodium-glucose cotransporter-2 inhibitors
Scheen AJ, et al. (2025). Cleveland Clinic Journal of MedicineBDOI - SGLT2-Inhibitoren Wechselwirkungen – Gesundheits-Lexikon DocMedicus
DocMedicus Redaktion (2024). DocMedicus GesundheitslexikonCLink - Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy
Perkovic V, Jardine MJ, Neal B, et al.; CREDENCE Trial Investigators (2019). New England Journal of MedicineAPMID:30990260DOI - Empagliflozin in Heart Failure with a Preserved Ejection Fraction
Anker SD, Butler J, Filippatos G, et al.; EMPEROR-Preserved Trial Investigators (2021). New England Journal of MedicineAPMID:34449189DOI - Dapagliflozin in Heart Failure with Mildly Reduced or Preserved Ejection Fraction
Solomon SD, McMurray JJV, Claggett B, et al. (2022). New England Journal of MedicineAPMID:36027570DOI - Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes
Neal B, Perkovic V, Mahaffey KW, et al.; CANVAS Program Collaborative Group (2017). New England Journal of MedicineAPMID:28605608DOI - Sodium-Glucose Cotransporter 2 Inhibitors Mechanisms of Action: A Review
Vallon V, Thomson SC, et al. (2022). Frontiers in MedicineBPMID:35004834DOI - Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes (EMPA-REG OUTCOME)
Zinman B, Wanner C, Lachin JM, et al. (2015). New England Journal of MedicineAPMID:26378978DOI - Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction (DAPA-HF)
McMurray JJV, Solomon SD, Inzucchi SE, et al. (2019). New England Journal of MedicineAPMID:31535829DOI - SGLT2 inhibitors in patients with heart failure with reduced ejection fraction: a meta-analysis of the EMPEROR-Reduced and DAPA-HF trials
Zannad F, Ferreira JP, Pocock SJ, et al. (2020). The LancetAPMID:32877652DOI - Prescribing SGLT2 Inhibitors in Patients With CKD: Expanding Indications and Practical Considerations
Rangaswami J, Bhalla V, Blair JEA, et al. (2022). Kidney Medicine / PMCBPMID:35812009DOI - Cardiovascular and Renal Outcomes with Empagliflozin in Heart Failure (EMPEROR-Reduced)
Packer M, Anker SD, Butler J, et al. (2020). New England Journal of MedicineAPMID:32865377DOI - Dapagliflozin in Patients with Chronic Kidney Disease (DAPA-CKD)
Heerspink HJL, Stefánsson BV, Correa-Rotter R, et al. (2020). New England Journal of MedicineAPMID:32970396DOI
Community Sources
Storage
Unopened
Store at room temperature (15–30 °C), dry and protected from light, per prescribing information.
Opened
Keep tablets in original packaging; no special requirements after opening.
Notes
Prescription medication; store out of reach of children. Observe expiration date. Dispose of unused tablets appropriately.